The resistance to these therapies in HER2+ breast cancer can partially be explained by the mechanisms described above, as the ADC is composed of an mAB that needs to bind to the extracellular domain of HER2 in order to have an effect; however, unique mechanisms of resistance to ADCs have been also described (Figure 2F). This evidence concerns the gene ERBB2 and breast cancer.